Keros Therapeutics, INC DEF 14A proxy statements

Keros Therapeutics is holding its 2026 Annual Meeting of Stockholders on June 3, 2026, to elect directors, ratify auditors, and vote on executive compensation.

Leading independent proxy advisory firm Glass Lewis & Co. has recommended Keros Therapeutics stockholders vote FOR all three of the company's director nominees at the upcoming Annual Meeting, countering an activist campaign by ADAR1 Capital Management.

Keros Therapeutics is actively pursuing a strategic review to maximize stockholder value, while facing pressure from ADAR1 Capital, which the company claims is disruptive to the process.

Keros Therapeutics files investor presentation and issues open letter to stockholders, urging them to vote for the company's director nominees amidst a strategic review process and a campaign by ADAR1 Capital Management.

Keros Therapeutics issues a supplement to its proxy statement addressing a shareholder's intention to withhold votes for two director nominees ahead of the 2025 Annual Meeting.

Keros Therapeutics addresses concerns raised by ADAR1 Capital Management, defends its board nominees, and highlights its ongoing strategic review process.

Keros Therapeutics has filed a definitive proxy statement related to its upcoming shareholder meeting.

Keros Therapeutics is holding its annual meeting to elect directors, ratify auditors, and conduct an advisory vote on executive compensation as the Board evaluates strategic alternatives.

Keros Therapeutics will hold its annual stockholders meeting virtually on May 30, 2024, to vote on director elections, auditor ratification, executive compensation, and vote frequency.

Keros Therapeutics announces its 2024 Annual Meeting of Stockholders to be held virtually on May 30, 2024, covering director elections, auditor ratification, executive compensation, and vote frequency.